(NASDAQ: TMDX) Transmedics Group's forecast annual revenue growth rate of 15.38% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.65%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Transmedics Group's revenue in 2026 is $668,468,000.On average, 15 Wall Street analysts forecast TMDX's revenue for 2026 to be $25,914,469,616, with the lowest TMDX revenue forecast at $24,721,297,876, and the highest TMDX revenue forecast at $27,008,123,689. On average, 15 Wall Street analysts forecast TMDX's revenue for 2027 to be $30,680,221,545, with the lowest TMDX revenue forecast at $29,086,205,129, and the highest TMDX revenue forecast at $32,658,785,318.
In 2028, TMDX is forecast to generate $35,646,049,060 in revenue, with the lowest revenue forecast at $32,533,954,796 and the highest revenue forecast at $39,078,888,415.